Atherosclerotic cardiovascular disease (ASCVD) represents a significant health challenge globally, with a rising incidence in Nigeria and other developing regions.1,2 High-density lipoprotein (HDL) and its associated apolipoproteins, namely apolipoprotein A1 (Apo A1) and apolipoprotein B (Apo B), along with HDL phospholipids, have garnered considerable attention for their intricate involvement in ASCVD progression. Here, APOA1 is linked to atherosclerosis.